Aclarion Adds First Private Practice Site to CLARITY Trial

Aclarion, Inc., a healthcare technology company leveraging biomarkers and augmented intelligence to pinpoint chronic low back pain, has announced the addition of Lanman Spinal Neurosurgery as a clinical site for its CLARITY trial. This 300-patient prospective, randomized, multi-center study evaluates Nociscan, the first evidence-supported SaaS platform that noninvasively helps physicians distinguish painful from nonpainful discs using MR Spectroscopy. Based in Beverly Hills, Lanman Spinal Neurosurgery is a leading private practice known for complex spinal procedures and early adoption of innovative technologies. Dr. Todd Lanman, a neurosurgeon with over 25 years of experience and a personal history of multiple spine surgeries, emphasized that Nociscan introduces a new layer of clarity beyond standard MRI. The inclusion of a private practice site reflects growing interest in integrating Nociscan into real-world clinical workflows, moving beyond academic medical centers. Aclarion expects an initial internal data readout and public disclosure of early interim results in Q4 2026. Chronic low back pain affects approximately 266 million people worldwide, and Nociscan has demonstrated a 97% surgical success rate when all Nociscan-positive discs are treated. The trial aims to generate high-quality evidence to advance this technology, which objectively quantifies chemical biomarkers associated with disc pain. For more information, visit the CLARITY Trial page or find a Nociscan center here.

The addition of Lanman Spinal Neurosurgery marks a crucial step in expanding the CLARITY trial, as private practice spine surgeons treat the majority of chronic low back pain patients. Ryan Bond, Chief Strategy Officer of Aclarion, noted the growing demand for precise, data-driven tools in everyday clinical practice. Dr. Lanman’s commitment to innovation and patient-centered care aligns with Aclarion’s mission to optimize treatment strategies. Nociscan receives MRS data from an MRI machine, extracts chemical biomarkers in the cloud, and uses proprietary algorithms to indicate if a disc may be a source of pain. This technology provides critical insights into pain location, helping physicians match the right procedure to the right patient. The CLARITY trial will evaluate changes in back pain using a 100mm VAS Back scale at 12 months, along with secondary endpoints. Aclarion’s forward-looking statements include expectations for patient enrollment and trial expansion, but the company cautions about risks detailed in SEC filings. For media inquiries, contact Jennie Kim at SPRIG Consulting.